TMCX+, 2450 Holcombe Boulevard
About Vyripharm BiopharmaceuticalsProvider of drug development services for debilitating diseases. Vyripharm Biopharma develops drugs to target cancer, PTSD, drug addiction and metabolic diseases and aims in improving clinical management through diagnosis and treatment with botanicals, synthetic pharmaceuticals and drug delivery systems.
Co-Founder & President, Research & Development: Elias Jackson Ph.D Co-Founder & Vice President, Research & Development: David Yang Board Member & Executive: Jerry Bryant Jr.
8 articles about Vyripharm Biopharmaceuticals
Vyripharm Enterprises Inc and ABB, Inc. collaborate on the design and development of Automation and Robotics to advance Testing Laboratory Platform for Public Health and Public Safety
Vyripharm Enterprises Inc. and ABB Robotics have signed an agreement towards the development of an automated laboratory testing platform.
Vyripharm International, Inc. and the National Yang-Ming University Signed a MOU to Develop VYR-206 as a Novel Diagnostic Approach for Neurological Disorders Outcomes Following Treatments
Vyripharm International, Inc., is a subsidiary of Vyripharm Enterprises, LLC, a privately held company formed for Partnerships and Joint Ventures with International Public or Private Organizations.
Vyripharm Biopharmaceuticals and Regis Technologies, Inc. Have Signed Off on a Master Drug Program Agreement for Expediting cGMP Manufacture of Our Antiviral Agents for Diagnostic Evaluation of COVID-19
Vyripharm Biopharmaceuticals, a subsidiary of Vyripharm Enterprises, LLC, a privately held company located in the Texas Medical Center in Houston, Texas, announced today that it has signed off on a Master Drug Program Agreement with Regis Technologies, Inc. Regis is a privately held contract development manufacturing organization (CDMO) in Morton Grove, Illinois.
Vyripharm Biopharmaceuticals Is in the Development Stage of a Novel Integrated Theranostic Approach for the Treatment of Viral Infections Such as COVID-19
Vyripharm Biopharmaceuticals announced that it will repurpose the development of a novel theranostic platform for the diagnosis, monitoring and treatment of viral infections such as SARS, MERS and COVID-19.
A summary of daily biopharma industry news. Please check out stories that are trending on March 27, 2020.
Vyripharm and WardMM Announce Clinical Trial Partnership for the Integration of Traditional Standard Pharmaceuticals With Medical Botanicals
The JV represents a global first in a collaboration to produce comprehensive precision pharmaceutical grade medicine, derived from medical botanicals.
Shimadzu Scientific Instruments, Inc. And VpH, A Division Of Vyripharm Biopharma, Establish The Medical Botanical Center Of Excellence At University Of Houston Innovation Center
Vyripharm Biopharma Issued Patent For Comprehensive Medical Cannabis Testing From Agriculture To Clinical Applications